Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients

Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study.

Source: ScienceDaily Headlines - January 9, 2015 Category: Science Source Type: news